Krönke Lab

The Krönke Lab focusses on Hematologic Malignancies at the Department of Hematology and Oncology, Charité – Universitätsmedizin Berlin

[nizar jacques bahlis @NBahlis]

Anti-BCMA TCE in newly diagnosed myeloma. New era is here, end of HCT? congrats @RaabMarc @RascheLeo https://t.co/qkK5AsaonW

[nizar jacques bahlis @NBahlis]

Protein-Genomics Myeloma Session #ASH24 chaired by Dr Paola Neri ⁦@FrancescoMaura4⁩ @kronkelab ⁦@fabianaperna⁩

[Keller-Lab@Charite @lab_keller]

Early View | Haematologica https://t.co/oiLGn0wlSK

Finally first results from our Phase 1 TCR study targeting MAGE-A1 in myeloma!
Hopefully more to come in advanced solid tumors where need for innovative (cellular) therapies is still HUGE.

[Keller-Lab@Charite @lab_keller]

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus | New England Journal of Medicine https://t.co/K9n4nq8Rzn

[Krönke Lab @KroenkeLab]

Wonderful collaboration with Philipp Mertins, Stefan Knop, DSMM study group, and many others!

[Krönke Lab @KroenkeLab]

Happy to share that our #proteogenomic study of multiple myeloma led by Evelyn Ramberger is out now @NatureCancer https://t.co/7Kl7mt4QT4
@MDC_Berlin @ChariteBerlin @berlinnovation

[Krönke Lab @KroenkeLab]

Our multiomics analysis including deep TMT-based (phospho)proteomics, RNA sequencing, and nanopore DNA sequencing of 138 primary multiple myeloma samples reveals new insights into disease biology and treatment opportunities

[Mick Milsom @MilsomMick]

We had a record number of (high quality) abstracts for this year’s Mol Hem workshop @EHA_Hematology annual meeting. Check out the 12 selected talks https://t.co/Rnq060oVr0

[Alesa Bricelj @AlesaBricelj]

Our paper on using heteroPROTACs to induce potent pan-IAP degradation is finally out! Check out our results from the IAP vs VHL&CRBN battle 🥊—> https://t.co/RaKwb2Jiq6
Very happy about this great collaboration with our established team 😁@IzidorSosic @c_steinebach, @KroenkeLab

[Haas Lab @haas_lab]

Excited to announce that our lab has been awarded an #ERC_StG grant to study immunological interactions in leukemias. Thanks to our team members, collaborators, friends and family for the constant support!
@berlinnovation @MDC_Berlin @ChariteBerlin @ERC_Research

[Izidor Sosič @IzidorSosic]

It's the E3 ligase Smac-down!🥊VHL and CRBN face IAPs head to head.🥊Who shall prevail? Welp, our preprint title gives it out, IAPs get totally K.O.'d. https://t.co/ad2aXooxoV. A great collaboration from @c_steinebach, @KroenkeLab, @AlesaBricelj and @IzidorSosic #TPD #PROTACs

[Krönke Lab @KroenkeLab]

@rschneiderlab @adamssperling @tarekmd91 @IreneGhobrial @TheBoettcherLab @PLMcCarthyMD @SykesLabMGH @c_j_gibson Congrats Adam, great work!

[Jana Ellegast @JanaMEllegastMD]

Very excited to share our latest work, now published online first in @CD_AACR!
Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts https://t.co/YbCMXGzI0l

[Mikołaj Słabicki @biomiko]

We employed the BTB domain of transcription factor BCL6 as small-molecule-controlled reversible oligomerization switch. Led by @lena_nitsch and my first corresponding author manuscript @CellRepMethods 1/16 https://t.co/zGYxviIUmO

[Krönke Lab @KroenkeLab]

Happy to announce our new work identifying cdk6 in lenalidomide resistant multiple myeloma published in @NatureComms https://t.co/DyRLBW9ojd great collaboration @ChariteBerlin @MDC_Berlin

[Ohad Hammer @ohadhammer]

First $ARVN, then $KYMR, now $NRIX PROTACS work!!! Not sure this class gets the credit it deserves for its huge potential. Still early days and chemistry isn't trivial but the potential here is huge: The ability to degrade every protein with an oral small molecule...

[Krönke Lab @KroenkeLab]

Check our new paper Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma | Blood Advances | American Society of Hematology https://t.co/SGFqgDE5aP

[Krönke Lab @KroenkeLab]

@c_steinebach @IzidorSosic 👍👍👍